Skip to content
Screener

NeoGenomics NEO Cash & Equivalents

Cash & Equivalents at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
$126M+24.8%
Labcorp Holdings logo
Labcorp HoldingsLH
$141.8M-78.1%
Quest Diagnostics logo
Quest DiagnosticsDGX
$626M+96.2%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
$30M+44.7%
Personalis, Inc. logo
Personalis, Inc.PSNL
$73.59M+3.7%
Guardant Health logo
Guardant HealthGH
$1.1B+37.0%

Other financials

Income statement

See full
Revenue$201.7M+11.2%
Gross profit$91.9M+18.9%
Operating income-$9.8M+79.5%
Net income$2.2M+105%
EPS (diluted)$0.02+106%

Balance sheet

See full
Total debt$448.4M+534%
Total equity$785.7M-8.0%
Total assets$1.4B-3.0%

Cash flow

See full
Operating cash flow$20.0M-1.8%
CapEx$8.2M+30.0%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$2B+182%
Enterprise value$2.3B+268%
P/S2.6×+1.6×

Profitability

See full
Gross margin43.9%0.0pp
Operating margin-8.9%-2.8pp
Net margin-6.8%-2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-6.3%-2.0pp
Debt / equity0.6×+0.5×
Current ratio3.6×-0.3×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001077183-26-000059
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from issuance of common stock upon exercise of stock options1,27374
Employee taxes paid related to net share settlement of restricted stock(3,168)(2,567)
Net cash used in financing activities(12,582)(201,484)
Net change in cash and cash equivalents, including cash classified within current assets held for sale(14,079)(212,235)
Less: net change in cash classified within current assets held for sale(54)
Net change in cash and cash equivalents(14,079)(212,289)
Cash and cash equivalents, beginning of period159,618367,012
Cash and cash equivalents, end of period$145,539$154,723

Item 1. Financial Statements (unaudited)

FAQ

What is NeoGenomics's cash & equivalents?
NeoGenomics (NEO) reported cash & equivalents of $145.54M in Q2 2026.
How has NeoGenomics's cash & equivalents changed year-over-year?
NeoGenomics's cash & equivalents decreased by 5.9% year-over-year, from $154.72M to $145.54M.
What is the long-term trend for NeoGenomics's cash & equivalents?
Over 5 years (2020 to 2025), NeoGenomics's cash & equivalents has grown at a -6.9% compound annual growth rate (CAGR), from $228.71M to $159.62M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about NeoGenomics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude